We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
First came the news that activist investor Starboard Value had bought up shares of Bristol-Myers Squibb with the intention of scuttling its planned $74 billion buyout of Celgene.